Literature DB >> 6939452

Acute nonlymphocytic leukemia: heterogeneity of stem cell origin.

P J Fialkow, J W Singer, J W Adamson, K Vaidya, L W Dow, J Ochs, J W Moohr.   

Abstract

Four patients with acute nonlymphocytic leukemia who were heterozygous for the X-chromosome-linked enzyme glucose-6-phosphate dehydrogenase (G6PD) were studied to determine the numbers and types of progenitor cells in which the disease arose. Both forms of enzyme were found in normal tissues, but the malignant blast cells showed only one G6PD, indicating that the disease was clonal at the time of testing. The observations that normal erythroid cells were present in two young patients at diagnosis and relapse indicate that the clone suppressed expression of normal granulopoiesis but did not prevent normal erythroid differentiation. In contrast to this situation, in two elderly patients, the disease involved stem cells multipotent for granulocytes, red cells, and platelets. These results indicate that acute nonlymphocytic leukemia is heterogeneous. In some patients, the disease is expressed in cells with differentiation restricted to the granulocyte-monocyte pathway; in others, it involves stem cells capable of differentiating to granulocytes-monocytes, platelets, and erythrocytes. This heterogeneity may reflect differences in causation and could have prognostic and therapeutic importance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6939452

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Acute myelogenous leukaemia in children.

Authors:  S O Lie
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

Review 2.  Clonal hematopoiesis.

Authors:  Max Jan; Benjamin L Ebert; Siddhartha Jaiswal
Journal:  Semin Hematol       Date:  2016-10-20       Impact factor: 3.851

Review 3.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

4.  Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro.

Authors:  R D Irons; W S Stillman; D B Colagiovanni; V A Henry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 5.  Cancer stem cells: lessons from leukaemia.

Authors:  D Bonnet
Journal:  Cell Prolif       Date:  2005-12       Impact factor: 6.831

6.  A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Authors:  Mao Zhang; Pariya Sukhumalchandra; Atim A Enyenihi; Lisa S St John; Sally A Hunsucker; Elizabeth A Mittendorf; Anna Sergeeva; Kathryn Ruisaard; Zein Al-Atrache; Patricia A Ropp; Haroon Jakher; Tania Rodriguez-Cruz; Gregory Lizee; Karen Clise-Dwyer; Sijie Lu; Jeffrey J Molldrem; Gary L Glish; Paul M Armistead; Gheath Alatrash
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

Review 7.  Hematopoietic stem cells and retroviral infection.

Authors:  Prabal Banerjee; Lindsey Crawford; Elizabeth Samuelson; Gerold Feuer
Journal:  Retrovirology       Date:  2010-02-04       Impact factor: 4.602

Review 8.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

9.  Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed.

Authors:  I D Bernstein; J W Singer; R G Andrews; A Keating; J S Powell; B H Bjornson; J Cuttner; V Najfeld; G Reaman; W Raskind
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

10.  DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients.

Authors:  Tina Bianco-Miotto; Damian J Hussey; Tanya K Day; Denise S O'Keefe; Alexander Dobrovic
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.